Ann: Becoming a substantial holder-AXP.AX, page-7

Companies always underestimate the FDA approval process. But this application is strong. Well conducted study (Best paper at US Plastic Surgery conference) current successful use in Australia, growing US demand due to change in medical policy of mandatory discussion about reconstruction after mastectomy, cancer related product. The little CO2 release valve was designed by a NASA engineer as per the space program and this seems to be the aspect of ongoing enquiry.
But I look at this situation a bit differently than a short term investor... First this will be approved. Second it will be the gold standard of care. Third all modifications or new devices will be referenced back to this approval giving AXP Mark 1 a huge advantage. Four - this device is well patented to stop copies. Five - it was recently $1.32 so the price today is the price to buy. We small investors missed 76c but the company raised decisively and was heavily oversubscribed. Six - IMO. Buy now wait until FDA approval and US release and watch your investment double - this opinion agreed by Canaccord who follow this one vigorously.
This is definitely an inflating investment prospect. (I worked hard to come up with that).

Tyremen